HK59397A - Paroxetine hydrochloride anhydrate substantially free of bound organic solvent - Google Patents

Paroxetine hydrochloride anhydrate substantially free of bound organic solvent Download PDF

Info

Publication number
HK59397A
HK59397A HK59397A HK59397A HK59397A HK 59397 A HK59397 A HK 59397A HK 59397 A HK59397 A HK 59397A HK 59397 A HK59397 A HK 59397A HK 59397 A HK59397 A HK 59397A
Authority
HK
Hong Kong
Prior art keywords
substantially free
paroxetine hydrochloride
organic solvent
hydrochloride anhydrate
anhydrate substantially
Prior art date
Application number
HK59397A
Other languages
English (en)
Inventor
Witold Jacewicz Victor
Ward Neal
Original Assignee
Smithkline Beecham P.L.C.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27267578&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK59397(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9502297.6A external-priority patent/GB9502297D0/en
Priority claimed from GBGB9503112.6A external-priority patent/GB9503112D0/en
Priority claimed from GBGB9509807.5A external-priority patent/GB9509807D0/en
Application filed by Smithkline Beecham P.L.C. filed Critical Smithkline Beecham P.L.C.
Publication of HK59397A publication Critical patent/HK59397A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK59397A 1995-02-06 1997-05-08 Paroxetine hydrochloride anhydrate substantially free of bound organic solvent HK59397A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9502297.6A GB9502297D0 (en) 1995-02-06 1995-02-06 Novel compound
GBGB9503112.6A GB9503112D0 (en) 1995-02-17 1995-02-17 Novel compound
GBGB9509807.5A GB9509807D0 (en) 1995-05-15 1995-05-15 Novel compounds

Publications (1)

Publication Number Publication Date
HK59397A true HK59397A (en) 1997-05-16

Family

ID=27267578

Family Applications (1)

Application Number Title Priority Date Filing Date
HK59397A HK59397A (en) 1995-02-06 1997-05-08 Paroxetine hydrochloride anhydrate substantially free of bound organic solvent

Country Status (47)

Country Link
EP (3) EP0808314B1 (cs)
JP (2) JP2915338B2 (cs)
KR (1) KR100289885B1 (cs)
CN (3) CN1289496C (cs)
AR (2) AR001982A1 (cs)
AT (1) AT407528B (cs)
AU (2) AU4786496A (cs)
BE (1) BE1009112A3 (cs)
BG (1) BG62967B1 (cs)
BR (1) BR9600534A (cs)
CA (4) CA2210022C (cs)
CH (3) CH688353A5 (cs)
CZ (1) CZ297171B6 (cs)
DE (3) DE69631298T2 (cs)
DK (2) DK11996A (cs)
DZ (1) DZ1989A1 (cs)
ES (1) ES2114471B1 (cs)
FI (3) FI111544B (cs)
FR (1) FR2730232B1 (cs)
GR (1) GR1002466B (cs)
HK (1) HK59397A (cs)
HU (1) HUP9600255A1 (cs)
IE (1) IE80500B1 (cs)
IL (1) IL117035A (cs)
IT (1) IT1289532B1 (cs)
LU (1) LU88711A1 (cs)
LV (1) LV11618B (cs)
MA (1) MA23802A1 (cs)
MC (1) MC2411A1 (cs)
MX (1) MX9600484A (cs)
MY (1) MY132529A (cs)
NL (1) NL1002248C2 (cs)
NO (3) NO301009B1 (cs)
NZ (1) NZ280943A (cs)
OA (1) OA10261A (cs)
PL (1) PL189247B1 (cs)
PT (1) PT101827B (cs)
RO (1) RO112426B1 (cs)
RU (1) RU2125052C1 (cs)
SE (1) SE521084C2 (cs)
SG (1) SG43787A1 (cs)
SI (2) SI9600036B (cs)
SK (1) SK283608B6 (cs)
TR (1) TR199600096A2 (cs)
TW (1) TW503238B (cs)
UA (1) UA49796C2 (cs)
WO (1) WO1996024595A1 (cs)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3882224B2 (ja) 1996-05-31 2007-02-14 旭硝子株式会社 パロキセチンの製造方法
EP1384720A1 (en) * 1996-06-13 2004-01-28 SUMIKA FINE CHEMICALS Co., Ltd. Process for drying paroxetine hydrochloride
JP2000514653A (ja) * 1996-07-15 2000-11-07 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 立体特異的分割のためのエステラーゼのスクリーニングおよびその使用
US6638948B1 (en) 1996-09-09 2003-10-28 Pentech Pharmaceuticals, Inc. Amorphous paroxetine composition
US5672612A (en) * 1996-09-09 1997-09-30 Pentech Pharmaceuticals, Inc. Amorphous paroxetine composition
CA2193939C (en) * 1996-12-24 2002-02-12 K.S. Keshava Murthy Useful form of anhydrous paroxetine hydrochloride
TR199903025T2 (xx) 1997-06-10 2000-07-21 Synthon B.V. 4-Fenilpiperidin bile�imleri.
ES2166205T3 (es) * 1997-08-08 2002-04-01 Aventis Pharma Gmbh Forma cristalina de amida del acido n-(4-trifluorometilfenil)-5-metilisoxazol-4-carboxilico.
GB9726907D0 (en) * 1997-12-19 1998-02-18 Smithkline Beecham Plc Novel compounds
CN1300286A (zh) * 1998-03-16 2001-06-20 史密丝克莱恩比彻姆有限公司 帕罗西丁的晶形
GB9806312D0 (en) * 1998-03-24 1998-05-20 Smithkline Beecham Plc Novel formulations
AU2003200534B2 (en) * 1998-03-24 2004-12-02 Smithkline Beecham Plc Paroxetine compositions
US6699882B2 (en) 1998-03-24 2004-03-02 Smithkline Beecham P.L.C. Paroxetine compositions
JP3796351B2 (ja) * 1998-04-13 2006-07-12 住友化学株式会社 パロキセチン塩酸塩無水和物の乾燥方法
GB9812941D0 (en) * 1998-06-16 1998-08-12 Smithkline Beecham Plc Method of treatment
CH689805A8 (fr) * 1998-07-02 2000-02-29 Smithkline Beecham Plc Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant.
ES2138937B1 (es) 1998-07-07 2000-10-01 Medichem Sa Polimorfo de maleato de paroxetina y formulaciones farmaceuticas que lo contienen.
AP2001002072A0 (en) * 1998-08-07 2001-03-31 Smithkline Becham P L C Process for the preparation of a non-crystalline anhydrate form of paroxetine hydrochloride
GB9824298D0 (en) * 1998-11-05 1998-12-30 Smithkline Beecham Plc Novel process
GB9826175D0 (en) * 1998-11-28 1999-01-20 Smithkline Beecham Plc Novel process
GB9826176D0 (en) * 1998-11-28 1999-01-20 Smithkline Beecham Plc Novel process
GB9826178D0 (en) * 1998-11-30 1999-01-20 Smithkline Beecham Plc Novel process
GB9826180D0 (en) * 1998-11-30 1999-01-20 Smithkline Beecham Plc Novel process
GB9826171D0 (en) * 1998-11-30 1999-01-20 Smithkline Beecham Plc Novel compounds
EP1408039A3 (en) * 1998-11-30 2004-05-12 Smithkline Beecham Plc Mixed paroxetine propan-2-ol solvates
GB9826242D0 (en) * 1998-11-30 1999-01-20 Smithkline Beecham Plc Novel process
GB9828767D0 (en) * 1998-12-29 1999-02-17 Smithkline Beecham Plc Novel process
IT1308629B1 (it) * 1999-02-23 2002-01-09 Recordati Chem Pharm Processo per la produzione di paroxetina.
WO2000054775A1 (de) * 1999-03-12 2000-09-21 Basf Ag Stabile pharmazeutische anwendungsform für paroxetin-anhydrat
GB9914583D0 (en) * 1999-06-22 1999-08-25 Smithkline Beecham Plc Novel process
GB9914585D0 (en) * 1999-06-22 1999-08-25 Smithkline Beecham Plc Novel process
SE9902550D0 (sv) * 1999-07-02 1999-07-02 Astra Ab New crystalline forms
GB9919001D0 (en) * 1999-08-12 1999-10-13 Smithkline Beecham Plc Novel process
GB9923446D0 (en) * 1999-10-04 1999-12-08 Smithkline Beecham Plc Novel process
GB9923445D0 (en) * 1999-10-04 1999-12-08 Smithkline Beecham Plc Novel process
GB9923439D0 (en) * 1999-10-04 1999-12-08 Smithkline Beecham Plc Novel process
HU226912B1 (en) * 2000-04-07 2010-03-01 Richter Gedeon Nyrt New paroxetin salt and medicament containing it
JPWO2002022609A1 (ja) * 2000-09-14 2004-01-22 旭硝子株式会社 実質的に有機溶媒を含まないパロキセチン塩類の製造方法
JP2005524656A (ja) * 2002-02-22 2005-08-18 テバ ファーマシューティカル インダストリーズ リミティド 新規中間物質を用いるパロキセチンの調製
KR20080055990A (ko) * 2005-11-22 2008-06-19 테바 파마슈티컬 인더스트리즈 리미티드 시나칼셋 ＨＣｌ의 결정형 및 이의 제조 방법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1422263A (en) * 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
GB8430581D0 (en) * 1984-12-04 1985-01-09 Ferrosan As Treatment
DE3688827T2 (de) 1985-10-25 1994-03-31 Beecham Group Plc Piperidinderivat, seine Herstellung und seine Verwendung als Arzneimittel.
US5017585A (en) * 1986-11-03 1991-05-21 Novo Nordisk A/S Method of treating calcium overload
GB8626936D0 (en) * 1986-11-11 1986-12-10 Ferrosan As Treatment
DK716088D0 (da) * 1988-12-22 1988-12-22 Ferrosan As Reduktion af piperidin-dion-derivater samt intermediat
DK715988D0 (da) * 1988-12-22 1988-12-22 Ferrosan As Etherifikation og dealkylering af piperidin-derivater samt intermediater
JPH06502854A (ja) * 1990-11-24 1994-03-31 ビーチャム・グループ・パブリック・リミテッド・カンパニー 老年痴呆、過食症、片頭痛または食欲不振の治療用のパロキセチンの使用
US5258517A (en) * 1992-08-06 1993-11-02 Sepracor, Inc. Method of preparing optically pure precursors of paroxetine
GB9325644D0 (en) * 1993-12-15 1994-02-16 Smithkline Beecham Plc Novel formulation

Also Published As

Publication number Publication date
DE69621777D1 (de) 2002-07-18
HU9600255D0 (en) 1996-03-28
LU88711A1 (fr) 1996-08-23
RU2125052C1 (ru) 1999-01-20
SE521084C2 (sv) 2003-09-30
UA49796C2 (uk) 2002-10-15
SI21923A (sl) 2006-06-30
AT407528B (de) 2001-04-25
CN1636993A (zh) 2005-07-13
CA2211522C (en) 1999-12-07
ES2114471B1 (es) 1999-08-16
EP1136490B1 (en) 2004-01-07
PT101827B (pt) 1997-08-29
CA2211522A1 (en) 1996-08-07
FI960519A0 (fi) 1996-02-05
MA23802A1 (fr) 1996-10-01
IL117035A (en) 2000-02-29
NO20015070L (no) 1996-08-07
MY132529A (en) 2007-10-31
DE69621777T2 (de) 2003-01-02
JPH08245620A (ja) 1996-09-24
MX9600484A (es) 1997-01-31
SK283608B6 (sk) 2003-10-07
WO1996024595A1 (en) 1996-08-15
NO301009B1 (no) 1997-09-01
IT1289532B1 (it) 1998-10-15
AU4332896A (en) 1996-08-15
RO112426B1 (ro) 1997-09-30
IL117035A0 (en) 1996-09-12
SI9600036B (sl) 2006-12-31
CZ297171B6 (cs) 2006-09-13
IE960104A1 (en) 1996-08-07
DK11996A (da) 1996-08-07
DZ1989A1 (fr) 2002-10-15
IE80500B1 (en) 1998-08-12
OA10261A (en) 1997-09-19
FR2730232A1 (fr) 1996-08-09
EP0808314A1 (en) 1997-11-26
PL189247B1 (pl) 2005-07-29
NO960472L (no) 1996-08-07
FI960519L (fi) 1996-08-07
CN1216055C (zh) 2005-08-24
LV11618A (lv) 1996-12-20
NO970939D0 (no) 1997-02-28
BR9600534A (pt) 1997-05-13
CA2210022C (en) 2005-09-13
CN1289496C (zh) 2006-12-13
NO20015070D0 (no) 2001-10-18
GR1002466B (el) 1996-11-06
KR960031409A (ko) 1996-09-17
LV11618B (en) 1997-04-20
EP1378508A1 (en) 2004-01-07
CH688353A5 (de) 1997-08-15
FI20030370L (fi) 2003-03-12
CA2168829A1 (en) 1996-08-07
FR2730232B1 (fr) 1997-08-01
AU701518C (en) 2006-12-07
FI20030162L (fi) 2003-02-03
CA2210022A1 (en) 1996-08-07
BG62967B1 (bg) 2000-12-29
ES2114471A1 (es) 1998-05-16
FI20030370A7 (fi) 2003-03-12
ITMI960203A0 (cs) 1996-02-05
CH689804A5 (de) 1999-11-30
SI21923B (sl) 2006-12-31
CA2210023C (en) 1999-02-09
AU701518B2 (en) 1999-01-28
ATA21096A (de) 2000-08-15
CZ32096A3 (en) 1996-08-14
PT101827A (pt) 1996-09-30
HUP9600255A1 (en) 1997-03-28
FI111544B (fi) 2003-08-15
DE69631298T2 (de) 2004-11-18
DE19603797A1 (de) 1996-08-14
SK14396A3 (en) 1996-11-06
ITMI960203A1 (it) 1997-08-05
NO311519B1 (no) 2001-12-03
NO301009B3 (cs) 2003-01-06
NL1002248C2 (nl) 1996-09-11
CN1310180A (zh) 2001-08-29
SG43787A1 (en) 1997-11-14
AR036856A2 (es) 2004-10-06
EP1136490A1 (en) 2001-09-26
NO970939L (no) 1996-08-07
NZ280943A (en) 1997-01-29
DE69631298D1 (de) 2004-02-12
CN1143643A (zh) 1997-02-26
CA2168829C (en) 1997-12-16
NO960472D0 (no) 1996-02-05
JPH11228571A (ja) 1999-08-24
CA2210023A1 (en) 1996-08-07
TR199600096A2 (tr) 1996-08-21
PL312646A1 (en) 1996-08-19
DE19603797C2 (de) 1998-11-12
JP2915338B2 (ja) 1999-07-05
BG100333A (bg) 1996-08-30
AR001982A1 (es) 1998-01-07
DK200100223A (cs) 2001-02-12
FI20030162A7 (fi) 2003-02-03
BE1009112A3 (fr) 1996-11-05
NL1002248A1 (nl) 1996-08-06
KR100289885B1 (ko) 2001-05-15
SI9600036A (en) 1996-10-31
MC2411A1 (fr) 1996-12-02
EP0808314B1 (en) 2002-06-12
TW503238B (en) 2002-09-21
CN1090187C (zh) 2002-09-04
SE9600406D0 (sv) 1996-02-05
MX198371B (cs) 2000-08-29
AU4786496A (en) 1996-08-27
CH689229A5 (de) 1998-12-31
SE9600406L (sv) 1996-08-07

Similar Documents

Publication Publication Date Title
HK59397A (en) Paroxetine hydrochloride anhydrate substantially free of bound organic solvent
CA2272584A1 (en) Novel substituted pyrazole derivatives for the treatment of cardiocirculatory diseases
CA2217006A1 (en) Novel substituted piperazine derivatives having tachykinin receptor antagonists activity
BG103740A (en) Phytostyrene composition for the prevention of the alzheimer's disease
ATE211732T1 (de) N-benzylpiperidin- und tetrahydropyridin-derivate
DE69816731D1 (de) Benzofuranon-derivate und verfahren zu ihrer herstellung
EA200100347A1 (ru) Метод и композиция для лечения и профилактики туберкулеза
YU12000A (sh) Supstituisani 1,2,3,4,5,6-heksahidro-2,6-metano-3-benzazocin -10-oli, postupak za njihovo pripremanje i njihova primena kao lekova
BG102707A (bg) Нови триазолопурини, метод за тяхното получаване и тяхното приложение като лекарствени средства
CA2215333A1 (en) Heterocyclic substituted piperazinone derivatives as tachykinin receptor antagonists
ATE270287T1 (de) 2,3-dihydro-1h-isoindolderivate, verfahren zu ihrer herstellung und ihre verwendung als hemmer der serotoninwiederaufnahme
KR960701075A (ko) 신규 2'-메틸리덴 뉴클레오티드 화합물, 그의 제조 방법 및 그의 약학적 용도[novel 2'-methylidenenucleotide compound, process for producing the same, and pharmaceutical use thereof]
ATE339423T1 (de) Verfahren zur herstellung von 4'-o-substituierten 4'-demethyl-1 desoxypodophyllotoxinderivaten und geometrischen isomeren davon ,und antikrebspräparat, das diese enthält
AU7589298A (en) 5-{(heteroaryl)alkyl}-3-oxo-pyrido{1,2-(a)}benzimidazole-4-c arboxamide derivatives useful in treating central nervous system disorders
WO2001053538A3 (en) Method for functional mapping of an alzheimer's disease gene network and for identifying therapeutic agents for the treatment of alzheimer's disease
WO2003087035A8 (en) 2,5-bis-diamine-'1,4! benzoquinone derivatives for the treatment of alzheimer's disease a process for their preparation and intermediates therefor
CA2275299A1 (en) Indane or dihydroindole derivatives
AU1209501A (en) Method for treating parkinson's disease by administering (-)-5-keto-2-n,n-di-n-propylamino-tetrahydrotetralin
FR2708610B1 (fr) Dérivés du carboxyméthylidènecycloheptimidazole, méthode pour leur fabrication et agents thérapeutiques les contenant.
UA70975C2 (uk) Похідні 1,4-діарил-2-фтор-1-бутен-3-олу, спосіб їх одержання та способи одержання похідних 1,4-діарил-2-фтор-1,3-бутадієну і 1,4-діарил-2-фтор-2-бутену
HK1020947A1 (en) Novel heterocyclic substituted pyrrolidine amide derivatives
TH55853A3 (cs)
TH20016A (th) กลูโคไพแรโนไซด์ เบนโซไธโอฟีน
TH25477A (th) วิธีการบำบัดการทำงานผิดปกติของกระเพาะปัสสาวะ
MX9707015A (es) Procedimiento para aislar galantamina.

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20130131